文摘
摘要目的:调查地区髓损伤及其与临床结果协会放射检查孤立综合症患者(pwRIS)。
背景:RIS被定义为多发性硬化症(MS)的白质病变特征在磁共振成像(MRI)在缺乏明显的临床症状。现有研究表明,脑容量低pwRIS与健康对照组(高碳钢)和高损伤体积与pwRIS贫困认知能力有关。区域髓状态及其与临床表现在pwRIS是未知的。髓鞘水成像(MWI)是一个定量,biologically-specific MRI技术评估髓磷脂在活的有机体内通过髓水分数(MWF)。
设计/方法:27 pwRIS(平均年龄:45年,23岁女性)和20高碳钢(平均年龄:43年,14雌性)接受MWI执行3 t。MWF从4个感兴趣的区域(roi)提取和比较pwRIS和高碳钢之间使用Mann-Whitney紫外线测试。每个ROI的MWF之间的相关性和定时25英尺(T25FW)走,9洞挂钩测试(9成,和符号数字形式测试(SDMT)进行评估使用皮尔逊相关性。
结果:皮质脊髓束MWF较低(RIS / HC: 0.207/0.230 (p = 0.004))和胼胝体(RIS / HC: 0.102/0.119 (p = 0.002))相比,pwRIS高碳钢。没有显著的扣带MWF差异(p = 0.86)或上纵束(SLF) (p = 0.093)。在pwRIS T25FW性能与MWF的皮质脊髓束(R =−0.53, p = 0.004)和胼胝体(R =−0.38, p = 0.049)。之间没有明显的相关性观察9 hpt或SDMT MWF的皮质脊髓束,胼胝体,扣带,或者SLF。
结论:MWI显示弥漫性脑白质髓鞘损伤pwRIS。髓损伤pwRIS与动态功能没有明显的临床症状。纵向评价MWI pwRIS将提供早期的洞察力和临床变化发展的机制。
披露:基恩先生收到了研究支持在英属哥伦比亚大学的医学院。约翰逊女士没有披露。李医生没有披露。Tam已收到博士研究的机构自然科学和工程研究委员会的支持。谭博士的机构已经得到实践的研究支持脊髓研究所。哦收到博士个人薪酬在5000 - 9999美元的范围为罗氏公司担任顾问。博士的机构哦收到个人薪酬在5000 - 9999美元的范围为Biogen-Idec担任顾问。哦收到博士个人薪酬在500 - 4999美元的范围为百时美施贵宝担任顾问。哦收到博士个人薪酬在5000 - 9999美元的范围为EMD-Serono担任顾问。哦收到博士个人薪酬在5000 - 9999美元的范围为Sanofi-Genzyme担任顾问。 Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Oh has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen-Idec. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme. The institution of Dr. Oh has received research support from Biogen-Idec. The institution of Dr. Oh has received research support from EMD-Serono. The institution of Dr. Oh has received research support from Biogen-Idec. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi Genzyme. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi Genzyme. The institution of Dr. Traboulsee has received research support from Roche. The institution of Dr. Traboulsee has received research support from Genzyme. Dr. Kolind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Kolind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Kolind has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Kolind has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. The institution of Dr. Kolind has received research support from Sanofi Genzyme. The institution of Dr. Kolind has received research support from Roche. The institution of Dr. Kolind has received research support from Biogen.
